British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

Seeking Alpha analyst and Investing Group leader, Manika Premsingh believes the worst is now behind GSK, adding that even though there is risk to core EPS growth of forecasts 10-12% for the full ...

The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim. Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could ...

Looking ahead, GSK maintains its guidance for the full year of 2024, expecting turnover growth between 7% to 9% and core operating profit growth between 11% to 13%. The company is optimistic about ...

We will deliver our fully reinvigorated portfolio to market efficiently and maximise the considerable commercial potential, ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GSK cuts 2024 vaccine sales forecast for second ... compared with estimates of 43.6 pence on sales of about 8 billion pounds. It kept full-year total sales and earnings forecasts unchanged.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

There are two molecules in phase 2, but with no patient data. The GSK news has hurt the stock. In my previous articles, I had bemoaned the fact that ANAB had few trials listed for its lead ...